News, features, and commentary about cancer-related issues
— News, features, and commentary about cancer-related issues
September 4, 2026
• 2 min read
The FDA approved ropeginterferon alfa-2b (Besremi) injection to treat adults with essential thrombocythemia, the first new therapy for the chronic blood cancer since the 1997 approval of anagrelide.
A national survey showed that almost 40% of men 55 or older had never had a prostate-specific antigen (PSA) screening test for prostate cancer. (MedStar Health)
AbbVie’s ultra-rare blood cancer ADC secured FDA clearance while AstraZeneca’s oral SERD for breast cancer remains in regulatory…
The FDA has approved a prefilled injection device for adults with polycythemia vera, according to a press release. The…
There have been several promising developments lately in cancer research and treatment, including a new drug approved by the FDA…
News, features, and commentary about cancer-related issues
The FDA approved a treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of…
Pioneering drug can halt advance of multiple myeloma for three times as long as standard treatments
